JP2019516775A - プロバイオティクス及び消化酵素の組成物並びにその調製方法及び使用 - Google Patents
プロバイオティクス及び消化酵素の組成物並びにその調製方法及び使用 Download PDFInfo
- Publication number
- JP2019516775A JP2019516775A JP2018562173A JP2018562173A JP2019516775A JP 2019516775 A JP2019516775 A JP 2019516775A JP 2018562173 A JP2018562173 A JP 2018562173A JP 2018562173 A JP2018562173 A JP 2018562173A JP 2019516775 A JP2019516775 A JP 2019516775A
- Authority
- JP
- Japan
- Prior art keywords
- lactobacillus
- billion cfu
- probiotics
- bifidobacterium
- billion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 123
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 123
- 239000000203 mixture Substances 0.000 title claims abstract description 122
- 102000038379 digestive enzymes Human genes 0.000 title claims abstract description 78
- 108091007734 digestive enzymes Proteins 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000004365 Protease Substances 0.000 claims abstract description 42
- 108010028554 LDL Cholesterol Proteins 0.000 claims abstract description 31
- 210000004369 blood Anatomy 0.000 claims abstract description 23
- 239000008280 blood Substances 0.000 claims abstract description 23
- 102100026189 Beta-galactosidase Human genes 0.000 claims abstract description 19
- 108010059881 Lactase Proteins 0.000 claims abstract description 19
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 19
- 229940116108 lactase Drugs 0.000 claims abstract description 19
- 241000124008 Mammalia Species 0.000 claims abstract description 18
- 239000004382 Amylase Substances 0.000 claims abstract description 17
- 108010065511 Amylases Proteins 0.000 claims abstract description 17
- 102000013142 Amylases Human genes 0.000 claims abstract description 17
- 235000019418 amylase Nutrition 0.000 claims abstract description 17
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 16
- 102000004882 Lipase Human genes 0.000 claims abstract description 16
- 108090001060 Lipase Proteins 0.000 claims abstract description 16
- 239000004367 Lipase Substances 0.000 claims abstract description 16
- 108010002430 hemicellulase Proteins 0.000 claims abstract description 16
- 229940059442 hemicellulase Drugs 0.000 claims abstract description 16
- 235000019421 lipase Nutrition 0.000 claims abstract description 16
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 15
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims abstract description 15
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims abstract description 15
- 102100022624 Glucoamylase Human genes 0.000 claims abstract description 15
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims abstract description 15
- 239000001573 invertase Substances 0.000 claims abstract description 15
- 235000011073 invertase Nutrition 0.000 claims abstract description 15
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 14
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 14
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 14
- 108090000526 Papain Proteins 0.000 claims abstract description 14
- 108010028144 alpha-Glucosidases Proteins 0.000 claims abstract description 14
- 102000016679 alpha-Glucosidases Human genes 0.000 claims abstract description 14
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 14
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 14
- 229940055729 papain Drugs 0.000 claims abstract description 14
- 235000019834 papain Nutrition 0.000 claims abstract description 14
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 13
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 13
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 13
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 12
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 12
- 229940004120 bifidobacterium infantis Drugs 0.000 claims abstract description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 108010004032 Bromelains Proteins 0.000 claims abstract description 11
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 11
- 235000019835 bromelain Nutrition 0.000 claims abstract description 11
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 11
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 9
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 9
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 9
- 241000186660 Lactobacillus Species 0.000 claims description 68
- 229940039696 lactobacillus Drugs 0.000 claims description 67
- 230000000529 probiotic effect Effects 0.000 claims description 46
- 102000004190 Enzymes Human genes 0.000 claims description 45
- 108090000790 Enzymes Proteins 0.000 claims description 45
- 229940088598 enzyme Drugs 0.000 claims description 45
- 241000186000 Bifidobacterium Species 0.000 claims description 40
- 239000002775 capsule Substances 0.000 claims description 40
- 108091005804 Peptidases Proteins 0.000 claims description 18
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 13
- 235000019419 proteases Nutrition 0.000 claims description 12
- 150000003626 triacylglycerols Chemical class 0.000 claims description 9
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 101710101928 Endo-1,4-beta-xylanase 2 Proteins 0.000 claims 3
- 229940079919 digestives enzyme preparation Drugs 0.000 claims 3
- 238000008214 LDL Cholesterol Methods 0.000 claims 2
- 239000007894 caplet Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 73
- 108010023302 HDL Cholesterol Proteins 0.000 abstract description 12
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000009467 reduction Effects 0.000 abstract description 4
- 230000036996 cardiovascular health Effects 0.000 abstract description 3
- 230000004580 weight loss Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 description 22
- 230000009469 supplementation Effects 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 17
- 208000029078 coronary artery disease Diseases 0.000 description 16
- 235000013305 food Nutrition 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 10
- 230000001332 colony forming effect Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 235000009200 high fat diet Nutrition 0.000 description 9
- 239000002417 nutraceutical Substances 0.000 description 8
- 235000021436 nutraceutical agent Nutrition 0.000 description 8
- 235000015872 dietary supplement Nutrition 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000001079 digestive effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 150000004666 short chain fatty acids Chemical class 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000013311 vegetables Nutrition 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 201000010538 Lactose Intolerance Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000012754 cardiac puncture Methods 0.000 description 4
- 210000002249 digestive system Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000009747 swallowing Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 210000001815 ascending colon Anatomy 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000015263 low fat diet Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 210000003384 transverse colon Anatomy 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 238000008620 Cholesterol Assay Methods 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000009084 cardiovascular function Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- -1 for example Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 235000006486 human diet Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 241000234670 Bromeliaceae Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
- 101710127332 Protease I Proteins 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930003811 natural phenol Natural products 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 239000008104 plant cellulose Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01008—Endo-1,4-beta-xylanase (3.2.1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01026—Beta-fructofuranosidase (3.2.1.26), i.e. invertase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01108—Lactase (3.2.1.108)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22002—Papain (3.4.22.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22032—Stem bromelain (3.4.22.32)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (32)
- 医薬組成物であって、ビフィドバクテリウム・インファンティス、ビフィドバクテリウム・ビフィダム、ラクトバチルス・アシドフィルス、ラクトバチルス・サリバリウス、ラクトバチルス・プランタルム、ラクトバチルス・ラムノサス、ビフィドバクテリウム・ロンガム、ラクトバチルス・カゼイ、及びラクトバチルス・パラカゼイを含むプロバイオティクスの製剤;ならびにアミラーゼ、グルコアミラーゼ、リパーゼ、ブロメライン、マルターゼ、ラクターゼ、ヘミセルラーゼ、キシラナーゼ、パパイン、及びインベルターゼを含む消化酵素の製剤を含む医薬組成物。
- 前記組成物の剤形が薬学的に許容される丸薬、錠剤、カプレット、カプセル、粉末、懸濁液、ゲル及び液体から成る群から選択される請求項1に記載の医薬組成物。
- 前記プロバイオティクスが116.20mgの総重量で存在する請求項2に記載の医薬組成物。
- 前記消化酵素が272.65mgの総重量で存在する請求項2に記載の医薬組成物。
- 前記プロバイオティクス及び消化酵素の製剤が複数のカプセルに含有されている請求項1に記載の医薬組成物。
- 前記プロバイオティクス及び消化酵素の製剤が、同一、単一のカプセルに存在する請求項5に記載の医薬組成物。
- 前記プロバイオティクスが、ビフィドバクテリウム・インファンティス−50〜70億cfu、ビフィドバクテリウム・ロンガム−7.5億〜20億cfu、ビフィドバクテリウム・ビフィダム−30〜50億cfu、ラクトバチルス・ラムノサス-50〜70億cfu、ラクトバチルス・アシドフィルス−10−30億cfu、ラクトバチルス・サリバリウス−10〜30億cfu、ラクトバチルス・プランタルム−10〜30億cfu、ラクトバチルス・カゼイ−7.5億〜20億cfu、ラクトバチルス・パラカゼイ−10〜30億cfuの量で存在する請求項1に記載の医薬組成物。
- 前記プロバイオティクスが、ビフィドバクテリウム・インファンティス−60億cfu、ビフィドバクテリウム・ロンガム−10億cfu、ビフィドバクテリウム・ビフィダム−40億cfu、ラクトバチルス・ラムノサス−60億cfu、ラクトバチルス・アシドフィルス−20億cfu、ラクトバチルス・サリバリウス−20億cfu、ラクトバチルス・プランタルム−20億cfu、ラクトバチルス・カゼイ−10億cfu、ラクトバチルス・パラカゼイ−20億cfuの量で存在する請求項7に記載の医薬組成物。
- 前記酵素が、ヘミセルラーゼ−5〜11mg、キシラナーゼ−2〜6mg、アミラーゼ−0.5〜2.5mg、グルコアミラーゼ−30〜70mg、マルターゼ−8〜12mg、パパイン−0.5〜3mg、プロテアーゼ、例えばブロメライン−13〜23mg、リパーゼ−18〜32mg、インベルターゼ−0.5〜3mg、ラクターゼ−8.0〜11mgの量で存在する請求項1に記載の医薬組成物。
- 前記酵素が、ヘミセルラーゼ−8mg、キシラナーゼ−3.9mg、アミラーゼ−1.33mg、グルコアミラーゼ−50mg、マルターゼ−10mg、パパイン−1.7mg、ブロメライン−18mg、リパーゼ-25 mg、インベルターゼ−1.5mg、及びラクターゼ−9.5mgの量で存在する請求項9に記載の医薬組成物。
- 医薬組成物であって、(a)ビフィドバクテリウム・インファンティス、ビフィドバクテリウム・ビフィダム、ラクトバチルス・アシドフィルス、ラクトバチルス・サリバリウス、ラクトバチルス・プランタルム、ラクトバチルス・ラムノサス GG、ビフィドバクテリウム・ロンガム、ラクトバチルス・カゼイ、ラクトバチルス・パラカゼイを含むプロバイオティクス製剤、及び(b)消化酵素の製剤を含む医薬組成物。
- 前記消化酵素が、a)プロテアーゼ、b)炭水化物消化酵素、c)繊維消化酵素、及び、d)リパーゼからなる群から選択される請求項11に記載の医薬組成物。
- 前記炭水化物消化酵素が、a)アミラーゼ、b)グルコアミラーゼ、c)ラクターゼ、d)インベルターゼ、及び、e)マルターゼからなる群から選択される請求項12に記載の医薬組成物。
- 前記繊維消化酵素が、a)キシラナーゼ、及び、b)ヘミセルラーゼから成る群から選択される請求項12に記載の医薬組成物。
- 前記医薬組成物の剤形が丸薬、錠剤、カプレット、カプセル、粉末、懸濁液、ゲル、及び液体から成る群から選択される請求項11に記載の医薬組成物。
- 前記プロバイオティクス及び消化酵素の製剤が、同一、単一の製剤で製剤化されている請求項11に記載の医薬組成物。
- 前記単一の製剤がカプセルである請求項16に記載の医薬組成物。
- 前記消化酵素の製剤が、少なくとも2つのプロテアーゼを含む請求項12に記載の医薬組成物。
- 必要とする対象においてLDLコレステロールを低下させるための薬剤の調製における、アミラーゼ、グルコアミラーゼ、リパーゼ、ブロメライン、マルターゼ、ラクターゼ、ヘミセルラーゼ、キシラナーゼ、パパイン、及びインベルターゼを含む消化酵素の製剤と組み合わせた、ビフィドバクテリウム・インファンティス、ビフィドバクテリウム・ビフィダム、ラクトバチルス・アシドフィルス、ラクトバチルス・サリバリウス、ラクトバチルス・プランタルム、ラクトバチルス・ラムノサス、ビフィドバクテリウム・ロンガム、ラクトバチルス・カゼイ、ラクトバチルス・パラカゼイを含むプロバイオティクス製剤の使用。
- 前記プロバイオティクス及び消化酵素の製剤がカプセル中に組み合わされる請求項19に記載の使用。
- 前記プロバイオティクス及び消化酵素が経口投与用に製剤化される請求項19に記載の使用。
- 前記プロバイオティクスが、ビフィドバクテリウム・インファンティス−50〜70億cfu、ビフィドバクテリウム・ロンガム−7.5億〜20億cfu、ビフィドバクテリウム・ビフィダム−30〜50億cfu、ラクトバチルス・ラムノサス−50〜70億cfu、ラクトバチルス・アシドフィルス−10〜30億cfu、ラクトバチルス・サリバリウス−10〜30億cfu、ラクトバチルス・プランタルム−10〜30億cfu、ラクトバチルス・カゼイ−7.5億〜20億cfu、ラクトバチルス・パラカゼイ−10〜30億cfuの量で存在する請求項19に記載の使用。
- 前記プロバイオティクスが、ビフィドバクテリウム・インファンティス−60億cfu、ビフィドバクテリウム・ロンガム−10億cfu、ビフィドバクテリウム・ビフィダム−40億cfu、ラクトバチルス・ラムノサス−60億cfu、ラクトバチルス・アシドフィルス−20億cfu、ラクトバチルス・サリバリウス−20億cfu、ラクトバチルス・プランタルム−20億cfu、ラクトバチルス・カゼイ−10億cfu、ラクトバチルス・パラカゼイ−20億cfuの量で存在する請求項22に記載の使用。
- 前記酵素が、ヘミセルラーゼ−5〜11mg、キシラナーゼ−2〜6mg、アミラーゼ−0.5〜2.5mg、グルコアミラーゼ−30〜70mg、マルターゼ−8〜12mg、パパイン−0.5〜3mg、プロテアーゼ、例えばブロメライン−13〜23mg、リパーゼ−18〜32mg、インベルターゼ−0.5〜3mg、ラクターゼ−8.0〜11mgの量で存在する請求項19に記載の使用。
- 前記酵素が、ヘミセルラーゼ−8mg、キシラナーゼ−3.9mg、アミラーゼ−1.33mg、グルコアミラーゼ−50mg、マルターゼ−10mg、パパイン−1.7mg、ブロメライン−18mg、リパーゼ−25mg、インベルターゼ−1.5mg、及びラクターゼ−9.5mgの量で存在する請求項24に記載の使用。
- 血中LDL−C及び/又はトリグリセリド濃度の低下を必要とする哺乳動物を同定すること、およびビフィドバクテリウム・インファンティス、ビフィドバクテリウム・ビフィダム、ラクトバチルス・アシドフィルス、ラクトバチルス・サリバリウス、ラクトバチルス・プランタルム、ラクトバチルス・ラムノサス、ビフィドバクテリウム・ロンガム、ラクトバチルス・カゼイ、ラクトバチルス・パラカゼイを含むプロバイオティクス製剤の混合物からなる特定の製剤を、アミラーゼ、グルコアミラーゼ、リパーゼ、ブロメライン、マルターゼ、ラクターゼ、ヘミセルラーゼ、キシラナーゼ、パパイン及びインベルターゼを含む消化酵素の製剤と組み合わせて、必要とする対象においてLDLコレステロール又はトリグリセリドを低下させるのに十分な量で前記哺乳動物に投与することを含む治療方法。
- 前記プロバイオティクス及び消化酵素の製剤がカプセル中に組み合わされる請求項26に記載の方法。
- 前記プロバイオティクス及び消化酵素が、経口投与用に製剤化される請求項26に記載の方法。
- 前記プロバイオティクスが、ビフィドバクテリウム・インファンティス−50〜70億cfu、ビフィドバクテリウム・ロンガム−7.5億及び20億cfu、ビフィドバクテリウム・ビフィダム−30〜50億cfu、ラクトバチルス・ラムノサス−50〜70億cfu、ラクトバチルス・アシドフィルス−10〜30億cfu、ラクトバチルス・サリバリウス−10〜30億cfu、ラクトバチルス・プランタルム−10〜30億cfu、ラクトバチルス・カゼイ−7.5億〜20億cfu、ラクトバチルス・パラカゼイ−10〜30億cfuの量で存在する請求項26に記載の方法。
- 前記プロバイオティクスが、ビフィドバクテリウム・インファンティス−60億cfu、ビフィドバクテリウム・ロンガム−10億cfu、ビフィドバクテリウム・ビフィダム−40億cfu、ラクトバチルス・ラムノサス−60億cfu、ラクトバチルス・アシドフィルス−20億cfu、ラクトバチルス・サリバリウス−20億cfu、ラクトバチルス・プランタルム−20億cfu、ラクトバチルス・カゼイ−10億cfu、ラクトバチルス・パラカゼイ−20億cfuの量で存在する請求項29に記載の方法。
- 前記酵素が、ヘミセルラーゼ−5〜11mg、キシラナーゼ−2〜6mg、アミラーゼ−0.5〜2.5mg、グルコアミラーゼ−30〜70mg、マルターゼ−8〜12mg、パパイン−0.5〜3mg、プロテアーゼ、例えばブロメライン−13〜23mg、リパーゼ−18〜32mg、インベルターゼ−0.5〜3mg、ラクターゼ−8.0〜11mgの量で存在する請求項19に記載の方法。
- 前記酵素が、ヘミセルラーゼ−8mg、キシラナーゼ−3.9mg、アミラーゼ−1.33mg、グルコアミラーゼ−50mg、マルターゼ−10mg、パパイン−1.7mg、ブロメライン−18mg、リパーゼ−25mg、インベルターゼ−1.5mg、及びラクターゼ−9.5mgの量で存在する請求項31に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2016/033976 WO2017204788A1 (en) | 2016-05-24 | 2016-05-24 | Composition of probiotics and digestive enzymes and method of preparing and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019516775A true JP2019516775A (ja) | 2019-06-20 |
JP2019516775A5 JP2019516775A5 (ja) | 2019-07-25 |
Family
ID=60411761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018562173A Ceased JP2019516775A (ja) | 2016-05-24 | 2016-05-24 | プロバイオティクス及び消化酵素の組成物並びにその調製方法及び使用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200323929A1 (ja) |
EP (1) | EP3463404A4 (ja) |
JP (1) | JP2019516775A (ja) |
KR (1) | KR102380198B1 (ja) |
CN (1) | CN109451727A (ja) |
AU (1) | AU2016408376B2 (ja) |
BR (1) | BR112018074355A2 (ja) |
CA (1) | CA3025512A1 (ja) |
IL (1) | IL263238A (ja) |
MX (1) | MX2018014500A (ja) |
RU (1) | RU2018144897A (ja) |
WO (1) | WO2017204788A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019169179A1 (en) * | 2018-02-28 | 2019-09-06 | Shafer Kim | Augmenting efficacy of cancer therapies using probiotic based compositions |
BR112020018360A2 (pt) * | 2018-03-09 | 2020-12-29 | Biohm Health Llc | Composições para uso no equilíbrio do microbioma |
CN109528776A (zh) * | 2018-06-08 | 2019-03-29 | 广东益可维健康科技有限公司 | 一种预防治疗口腔疾病的复合益生菌含片及其制备方法 |
CN109566935A (zh) * | 2018-12-06 | 2019-04-05 | 张秋环 | 综合益生菌复合粉固体饮料的制备方法 |
TWI740101B (zh) * | 2019-02-12 | 2021-09-21 | 大江生醫股份有限公司 | 降膽固醇之益生菌株的用途 |
KR102119133B1 (ko) | 2019-05-02 | 2020-06-26 | 선정완 | 유산균 분말 및 노니 분말을 포함하는 프로바이오틱스 조성물 |
CA3148749A1 (en) * | 2019-08-30 | 2021-03-04 | Hem Pharma Inc. | Method for screening personalized intestinal environment-improving material and composition therefor |
KR102335928B1 (ko) * | 2019-10-02 | 2021-12-08 | 한국생명공학연구원 | 비만의 예방, 치료 또는 개선용 조성물 |
CN111213885A (zh) * | 2020-01-20 | 2020-06-02 | 齐海心 | 一种具有调节血脂功效的益生菌组合物及其制备方法与应用 |
TW202203950A (zh) * | 2020-03-30 | 2022-02-01 | 香港商香港微生物菌群創新中心有限公司 | 微生物在調節體重和膽固醇水準中的用途 |
CN111558033A (zh) * | 2020-05-14 | 2020-08-21 | 广州中昱医学生物科技有限公司 | 一种口腔清洁组合物及其应用 |
CN112021575A (zh) * | 2020-09-17 | 2020-12-04 | 泉州亚林新材料科技有限公司 | 一种益生菌组合物及其制备方法 |
CN113244408A (zh) * | 2021-06-02 | 2021-08-13 | 河北源民生物科技有限公司 | 一种适用于肠胃的益生菌组合物 |
CN115025132B (zh) * | 2022-06-09 | 2024-01-30 | 康永波 | 一种合生元组合物及其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7432097B2 (en) * | 1997-08-13 | 2008-10-07 | Verenium Corporation | Phytases, nucleic acids encoding them and methods of making and using them |
US6436451B1 (en) * | 1999-03-26 | 2002-08-20 | Eggland's Best, Inc. | Method of reducing cholesterol in chicken eggs |
US6368617B1 (en) * | 2001-05-15 | 2002-04-09 | Reliv' International, Inc. | Dietary supplement |
US20040071685A1 (en) * | 2002-10-09 | 2004-04-15 | Devin Houston | Compositions and methods for increasing the bioavailability of plant polyphenols |
GB2465814B (en) * | 2008-06-19 | 2011-10-26 | Tarig Sayed Mustafa Arbab | Method,composition and device for the treatment of enzymes and saccharides disorders |
US8257694B2 (en) * | 2009-05-14 | 2012-09-04 | Product Partners, Llc | Nutritional compositions for reducing oxidative damage |
CN102906251B (zh) * | 2010-04-26 | 2016-11-16 | 诺维信公司 | 酶颗粒剂 |
US9301983B2 (en) * | 2014-03-07 | 2016-04-05 | Genmont Biotech Inc. | Composition and method of Lactobacillus reuteri GMNL-89 in treating type 2 diabetes |
AU2015258769A1 (en) * | 2014-05-12 | 2016-12-01 | Medlab Ip Pty Ltd | Probiotic compositions and uses thereof for treatment of obesity-related disorders |
AU2015100952A4 (en) * | 2014-07-17 | 2015-08-20 | Pharm-A-Care Laboratories Pty Ltd | Probiotic- and enzyme-containing compositions and uses thereof |
-
2016
- 2016-05-24 CN CN201680086942.3A patent/CN109451727A/zh active Pending
- 2016-05-24 KR KR1020187037308A patent/KR102380198B1/ko active IP Right Grant
- 2016-05-24 BR BR112018074355-0A patent/BR112018074355A2/pt not_active Application Discontinuation
- 2016-05-24 EP EP16903312.3A patent/EP3463404A4/en not_active Withdrawn
- 2016-05-24 US US16/304,123 patent/US20200323929A1/en not_active Abandoned
- 2016-05-24 JP JP2018562173A patent/JP2019516775A/ja not_active Ceased
- 2016-05-24 AU AU2016408376A patent/AU2016408376B2/en not_active Ceased
- 2016-05-24 RU RU2018144897A patent/RU2018144897A/ru not_active Application Discontinuation
- 2016-05-24 CA CA3025512A patent/CA3025512A1/en not_active Abandoned
- 2016-05-24 WO PCT/US2016/033976 patent/WO2017204788A1/en unknown
- 2016-05-24 MX MX2018014500A patent/MX2018014500A/es unknown
-
2018
- 2018-11-22 IL IL263238A patent/IL263238A/en unknown
Non-Patent Citations (1)
Title |
---|
HALL, SEAN;VITETTA, LUIS;COULSON, SAMANTHA: "PROBIOTIC-AND ENZYME-CONTAINING COMPOSITIONS AND USES THEREOF", オーストラリア特許公報, vol. AU 2015100952 A4 オーストラリア特許, JPN5019004630, 20 August 2015 (2015-08-20), AU, ISSN: 0004265030 * |
Also Published As
Publication number | Publication date |
---|---|
CN109451727A (zh) | 2019-03-08 |
RU2018144897A (ru) | 2020-06-25 |
US20200323929A1 (en) | 2020-10-15 |
BR112018074355A2 (pt) | 2019-03-06 |
AU2016408376B2 (en) | 2020-10-22 |
KR102380198B1 (ko) | 2022-03-29 |
IL263238A (en) | 2018-12-31 |
KR20190015718A (ko) | 2019-02-14 |
EP3463404A1 (en) | 2019-04-10 |
WO2017204788A1 (en) | 2017-11-30 |
EP3463404A4 (en) | 2020-03-11 |
MX2018014500A (es) | 2019-04-15 |
AU2016408376A1 (en) | 2019-01-17 |
RU2018144897A3 (ja) | 2020-06-25 |
CA3025512A1 (en) | 2017-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016408376B2 (en) | Composition of probiotics and digestive enzymes and method of preparing and using the same | |
JP6882931B2 (ja) | プレバイオティック製剤および使用方法 | |
JP6129821B2 (ja) | プレバイオティクスとしての、精製された2’−フコシルラクトース、3−フコシルラクトース、およびラクトジフコテトラオースの使用 | |
EP1513541B1 (en) | Method for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract | |
EP3986163A2 (en) | Microbial compositions and methods for producing upgraded probiotic assemblages | |
JP2013518842A (ja) | 乳糖不耐症またはラクターゼ欠乏症から起こる症状の治療に使用するための組成物 | |
Peng et al. | Probiotics and Prebiotics on Intestinal Flora and Gut Health | |
Code | Human strain probiotic to support intestinal health in adults and children | |
Rao et al. | Probiotics and Diet for Chronic Diseases Prevention |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190520 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190520 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200817 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201215 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20210511 |